Popular terms

Isoquinolin topics
Isoquinolin
Quinoline Derivatives
Carbon Atoms
Praziquantel
Crystallin
Pharmaceutically Acceptable Salt
Cycloalkyl
Alkyl Group
Sulfonamide
Solifenacin
Cancer Cells
Cancer Cell
Viral Infection
Human Immunodeficiency Virus
Immunodeficiency

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Isoquinolin patents



      

This page is updated frequently with new Isoquinolin-related patent applications.




Date/App# patent app List of recent Isoquinolin-related patents
05/19/16
20160136166 
 Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds patent thumbnailnew patent Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone compounds
Tetrahydroisoquinolin-2-yl-(quinazolin-4-yl)methanone derivatives represented by formula (i), pharmacologically acceptable salts thereof, and compositions containing such compounds are described. Methods for treating hyperproliferative disorders by administering the compounds are also described.
Rexahn Pharmaceuticals, Inc.


05/05/16
20160122338 
 Novel photochromic tetrahydroindolizines patent thumbnailNovel photochromic tetrahydroindolizines
Photochromic tetrahydroindolizines (this) bearing dihydroisoquinoline derivatives as heterocyclic bases and central fluorene groups have been synthesized via different chemical and photochemical pathways. Three alternative pathways for the synthesis of the target photochromic thi-based pyridazinopyrrolo[1,2-b]isoquinolines via in situ trapping with hydrazine hydrate are also provided.
Umm Al-qura University


05/05/16
20160120859 
 Pharmaceutical formulations of a hif hydroxylase inhibitor patent thumbnailPharmaceutical formulations of a hif hydroxylase inhibitor
The present disclosure relates to pharmaceutical formulations of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid and methods of use thereof.. .
Fibrogen, Inc.


04/14/16
20160101099 
 H3 receptor antagonist for use in the treatment of alzheimer's disease patent thumbnailH3 receptor antagonist for use in the treatment of alzheimer's disease
This disclosure relates to methods of using 2-(cyclohexylmethyl)-n-{2-[(2s)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of alzheimer's disease, other tauopathies and related neurodegenerative diseases.. .

03/31/16
20160090364 
 Phthalazinones and isoquinolinones as rock inhibitors patent thumbnailPhthalazinones and isoquinolinones as rock inhibitors
Or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective rock inhibitors.

03/24/16
20160083385 
 Pyrazinoisoquinoline compounds patent thumbnailPyrazinoisoquinoline compounds
Where the designation (r) indicates that the designated carbon has the (r) stereochemistry; and wherein z1 is hydrogen or fluorine; z2 is hydrogen, deuterium, or fluorine; z3 is deuterium; z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both z1 and z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel..

03/24/16
20160083351 
 Tetrahydroisoquinolines as selective nadph oxidase 2 inhibitors patent thumbnailTetrahydroisoquinolines as selective nadph oxidase 2 inhibitors
Wherein “” represents a single or double bond, r1 is hydrogen, halogen, lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; ra is hydrogen, —ch2r2, r3, or —so2r4; r2 is lower aliphatic, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; r3 is substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; r4 is lower aliphatic, or substituted or unsubstituted aryl; and r5 is hydrogen, halogen, or lower aliphatic.. .

03/24/16
20160081999 
 Synthesis and use of dual tyrosyl-dna phosphodiesterase i (tdp1) - topoisomerase i (top1) inhibitors patent thumbnailSynthesis and use of dual tyrosyl-dna phosphodiesterase i (tdp1) - topoisomerase i (top1) inhibitors
The invention described herein pertains to the synthesis and use of certain n-substituted indenoisoquinoline compounds which inhibit the activity tyrosyl-dna phosphodiesterase i (tdp1) or topoisomerase i (top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel n-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel n-substituted indenoisoquinoline compounds..
Purdue Research Foundation


03/17/16
20160075715 
 Substituted tetrahydroisoquinoline compounds as factor xia inhibitors patent thumbnailSubstituted tetrahydroisoquinoline compounds as factor xia inhibitors
Or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..

03/17/16
20160075688 
 New 3,4-dihydro-2h-isoquinoline-1-one and  2,3-dihydro-isoindol-1-one compounds patent thumbnailNew 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
Wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, r13, r14, r15, a, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.. .

03/17/16
20160075687 

New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds


Wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, r13, r14, r15, a, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.. .

03/17/16
20160075686 

New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds


Wherein r1, r2, r3, r4, r5, r6, r7, r8, r9, r10, r11, r12, r13, r14, a, b, m, n and p are as described herein, compositions including the compounds and methods of using the compounds.. .

03/17/16
20160075657 

Tetrahydroisoquinoline derivatives, pharmaceutical compositions and uses thereof


Wherein r1 to r6, n and m are as defined in the description and claims, to their use as medicaments, to methods for their therapeutic use and to pharmaceutical compositions containing them.. .

03/03/16
20160060263 

Pyrazinoisoquinoline compounds


This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel.
Concert Pharmaceuticals, Inc.


02/25/16
20160052889 

Phenoxyethyl dihydro-1h-isoquinoline compounds


The present invention provides a compound of the formula i: wherein r is h or f; or a pharmaceutically acceptable salt thereof.. .
Eli Lilly And Company


02/18/16
20160046640 

Substituted 7-azabicycles and their use as orexin receptor modulators


The present invention is directed to compounds of formula i: wherein ring a is phenyl, naphihalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyi, tlisazolyl, isoxazolvl, pyrazolyl, imidazothiazolyi, benzimidazolyl, or indazolyi; r1 is h, alky], aikoxy, hydroxyalkylene, oh, halo, phenyl, triazolyl, oxazolyl, isoxazofyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, piperazinyl, pyrazolyl, oxadiazolvl, pyrrolidinyl, thiophenyi, morpholinyl, or dialkyiamino; r2 is h, alkyl, aikoxy, hydroxyalkylene, or halo; z is nh, n-alkyl, or o; r5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazmyl, qumazolinyi, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, aikoxy, or halo; and n is 0 or 1, methods of making the compounds of formula 1 are also described. The invention also relates to pharmaceutical compositions comprising compounds of formula i.
Janssen Pharmaceutica Nv


02/18/16
20160046583 

Isoquinoline derivatives


For the treatment of schizophrenia, obsessive-compulsive personality disorder, depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, parkinson's disease, dementia, alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine or cocaine.. .

02/11/16
20160039807 

Novel dihydropyrimidinoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders (gpr84 antagonists)


Wherein cy, l1, g, and r1 are as described herein. The present invention relates to novel compounds according to formula (i) that antagonize gpr84, a g-protein-coupled receptor that is involved in inflammatory conditions, and methods for the production of these novel compounds, pharmaceutical compositions comprising these compounds, and methods for the prevention and/or treatment of inflammatory conditions (for example inflammatory bowel diseases (ibd), rheumatoid arthritis, vasculitis), lung diseases (e.g.

02/11/16
20160039786 

Method for producing 3,4-dihydroisoquinoline derivatives and production intermediates of same


Provided are an efficient method for producing 3,4-dihydroisoquinoline derivatives and useful production intermediates thereof. Provided is a method for producing 3,4-dihydroisoquinoline derivatives represented by general formula (1), comprising converting a compound represented by general formula (3) in the presence of acid after reacting with an aniline derivative, or converting a compound represented by general formula (3) by reacting with an aniline derivative in the presence of an acid..
Mitsui Chemicals Agro, Inc.


02/11/16
20160038503 

Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives


The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell lymphoma).

01/28/16
20160024051 

Salts and solid forms of isoquinolinones and composition comprising and methods of using the same


Solid forms of chemical compounds that modulate kinase activity, including pi3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including pi3 kinase activity, are described herein. Also provided herein are processes for preparing compounds, solid forms thereof, and pharmaceutical compositions thereof..
Infinity Pharmaceuticals, Inc.


01/28/16
20160022675 

Processes for preparing tetrahydroisoquinolines


Disclosed are processes for preparing tetrahydroisoquinolines, intermediates useful in the preparation of tetrahydroisoquinolines, processes for preparing such intermediates, and compositions comprising the tetrahydroisoquinolines and other compounds, e.g, intermediates and by-products of the processes described herein. Pharmaceutical compositions comprising tetrahydroisoquinolines, methods of using tetrahydroisoquinolines in the treatment of depression are also disclosed..
Bristol-myers Squibb Company


01/21/16
20160016965 

Novel mixed μ agonist/ δ antagonist opioid analgesics with reduced tolerance liabilities and uses thereof


An opioid narcotics used for the treatment of moderate-to-severe pain that primarily exert their analgesic effects through μ receptors. Although, traditional μ agonists can cause undesired side effects, including tolerance, addition of δ antagonists can attenuate said side effects.
West Virginia University


01/21/16
20160016951 

Novel naphthyridines and isoquinolines and their use as cdk8/19 inhibitors


The present invention relates to naphthyridine and isoquinoline compounds, and pharmaceutically acceptable compositions thereof, useful as inhibitors of cdk8/19, and for the treatment of cdk8/19-related disorders.. .
Cancer Research Technology, Ltd.


01/21/16
20160016933 

Isoquinolines as potassium ion channel inhibitors


A compound of formula (i) (i) wherein a, r1, r1a, r3 and r24 are described herein. The compounds are useful as inhibitors of potassium channel function and in the treatment and prevention of arrhythmia, ikur-associated disorders, and other disorders mediated by ion channel function..
Bristol-myers Squibb Company


01/14/16
20160009653 

Cyanoisoquinoline compounds and methods of use thereof


The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoictin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:.
Fibrogen, Inc.


01/14/16
20160008363 

Drug combination


The invention provides a composition which comprises (a) a pde3/pde4 inhibitor which is 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a β2-adrenergic receptor agonist.. .
Verona Pharma Plc


01/07/16
20160002170 

Crystalline forms of -acetic acid


The present disclosure relates to crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoquinoline-3-carbonyl]-amino}-acetic acid (compound a), the process of preparing crystalline forms of compound a, the pharmaceutical compositions containing them, and the methods of use thereof.. .
Fibrogen, Inc.


01/07/16
20160000790 

Drug combination


The invention provides a composition which comprises (a) a pde3/pde4 inhibitor which is 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a muscarinic receptor antagonist.. .
Verona Pharma Plc


12/24/15
20150366864 

Crystalline form of 6-[(4s)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine


The present disclosure generally relates to a crystalline form of 6-[(4s)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. The present disclosure also generally relates to pharmaceutical compositions comprising the crystalline form, as well of methods of using a crystalline form in the treatment of depression and other conditions and methods for obtaining such crystalline form..
Albany Molecular Research, Inc.


12/17/15
20150364702 

Iridium complex and organic light-emitting device including the same


The present invention provides a novel iridium complex and an organic light-emitting device including the novel iridium complex. The novel iridium complex includes three ligands, and two of them have a phenyl-naphtho[2,1-f]isoquinoline skeleton.
Canon Kabushiki Kaisha


12/17/15
20150361067 

Substituted dihydroisoquinolinone compounds


In which r1, r2, r3, r4, l, x and z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.. .

12/17/15
20150359787 

Tetrahydroisoquinolin-1-one derivative or salt thereof


To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (ibs). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (bb2) receptor antagonistic action.
Seldar Pharma Inc.


12/10/15
20150353505 

Phthalazinones and isoquinolinones as rock inhibitors


The present invention provides compounds of formula (i) or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective rock inhibitors.
Bristol-myers Squibb Company


12/10/15
20150353498 

Substituted isoquinolines as crth2 receptor modulators


The invention provides certain substituted isoquinolines of the formula (i), and their pharmaceutically acceptable salts and esters. The invention also provides pharmaceutical compositions comprising for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of crth2 function..
Merck Sharp & Dohme Corp.


12/03/15
20150344434 

Tetrahydro- and dihydro-isoquinoline prmt5 inhibitors and uses thereof


Described herein are compounds of formula (a), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting prmt5 activity.
Epizyme, Inc.


12/03/15
20150344433 

Prmt5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof


Described herein are compounds of formula (a), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting prmt5 activity.
Epizyme, Inc.


11/26/15
20150336951 

Process for the preparation of a dpp-iv inhibitor


Wherein r1, r2 and r3 are each independently hydrogen, halogen, hydroxy, lower alkyl, lower alkoxy or lower alkenyl, wherein lower alkyl, lower alkoxy and lower alkenyl may optionally be substituted by lower alkoxycarbonyl, aryl or heterocyclyl, and the pharmaceutically acceptable salts thereof. The invention also relates to two crystalline forms of (2s,3s,11bs)-1-(2-amino-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-3-yl)-4(s)-fluoromethyl-pyrrolidin-2-one dihydrochloride, which are form a and form b and to an amorphous form of said compound..

11/26/15
20150335634 

Isoquinoline alkaloid derivative for activating amp-dependent protein kinase


The present invention provides a method for activating the amp-dependent protein kinase (ampk) in a subject comprising administering the subject with a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound having the general formula i, preferably salsolinol or reticuline. The pharmaceutical composition is able to activate ampk, and thus is effective in the regulation of cell growth and metabolism, and the treatment of ampk associated diseases..
Zih Yuan Tang Biotechnology Co., Ltd


11/19/15
20150333279 

Organic light-emitting element and display apparatus


Provided is an organic light-emitting element having high luminous efficiency and a long lifetime. The organic light-emitting element includes a pair of electrodes and an organic compound layer placed between the pair of electrodes, in which the organic compound layer includes an iridium complex having a benzo[f]isoquinoline of a specific structure as a ligand and a metal complex compound of a specific structure..
Canon Kabushiki Kaisha


11/19/15
20150329698 

Thermoplastic resin composition


In the chemical formulae (1) and (2) above, r1 and r2 each independently represent a substituted or unsubstituted linear, branched, or cyclic alkyl group having from 1 to 30 carbon atoms, a substituted or unsubstituted aryl group having from 6 to 30 carbon atoms, or a substituted or unsubstituted arylalkyl group having from 7 to 31 carbon atoms, a is a linear or branched alkylene group having from 2 to 4 carbon atoms, n represents an integer of 0 to 50, q1 and q2 each independently represent at least one kind selected from the group consisting of an ammonium ion, an imidazolium ion, a pyridinium ion, a pyrrolidinium ion, a pyrrolinium ion, a piperidinium ion, a pyrazinium ion, a pyrimidinium ion, a triazolium ion, a triazinium ion, a quinolinium ion, an isoquinolinium ion, an indolinium ion, a quinoxalinium ion, a piperazinium ion, an oxazolinium ion, a thiazolinium ion, and a morpholinium ion.. .

11/19/15
20150328224 

Substituted 7-azabicycles and their use as orexin receptor modulators


Wherein ring a is phenyl, naphthalenyl, pyridyl, quinolinyl, isoquinolinyl, imidazopyridyl, furanyl, thiazolyl, isoxazolyl, pyrazolyl, imidazothiazolyl, benzimidazolyl, or indazolyl; r1 is h, alkyl, alkoxy, hydroxyalkylene, oh, halo, phenyl, triazolyl, oxazolyl, isoxazolyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, piperazinyl, pyrazolyl, oxadiazolyl, pyrrolidinyl, thiophenyl, morpholinyl, or dialkylamino; r2 is h, alkyl, alkoxy, hydroxyalkylene, or halo; z is nh, n-alkyl, or o; r5 is pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, quinazolinyl, quinoxalinyl, pyrazolyl, benzoxazolyl, imidazopyrazinyl, triazolopyrazinyl, optionally substituted with a one or two substituents independently selected from the group consisting of alkyl, alkoxy, or halo; and n is 0 or 1. Methods of making the compounds of formula i are also described.

11/12/15
20150322015 

Crystalline forms of a prolyl hydroxylase inhibitor


The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. .
Fibrogen, Inc.


11/05/15
20150315200 

Substituted tetrahydroisoquinoline compounds as factor xia inhibitors


Or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..

10/22/15
20150303386 

Organic light-emitting device and display apparatus


Provided is an organic light-emitting device improved in emission efficiency and lifetime. The organic light-emitting device includes a pair of electrodes and an organic compound layer disposed between the pair of electrodes, in which: the organic compound layer includes a benzo[f]isoquinoline iridium complex of a specific structure and a hydrocarbon compound of a specific structure; and the hydrocarbon compound is a compound formed only of an sp2 carbon atom and a hydrogen atom..
Canon Kabushiki Kaisha


10/22/15
20150299246 

N-substituted indenoisoquinolines and syntheses thereof


N-substituted indenoisoquinoline compounds, and pharmaceutical formulations of n-substituted indenoisoquinoline compounds are described. Also described are processes for preparing n-substituted indenoisoquinoline compounds.
The Government Of The Usa As Represented By The Secretary Of The Dept Of Health And Human Services


10/22/15
20150299159 

Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds


Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents.
Aerie Pharmaceuticals, Inc.


10/22/15
20150297581 

Rho kinase inhibitors


Disclosed are novel substituted 2h-isoquinolin-1-one and 3h-quinazolin-4-one derivatives useful as inhibitors of rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.. .
Aerie Pharmaceuticals, Inc.


10/15/15
20150295188 

Organic light-emitting element


Provided is an organic light-emitting element improved in luminous efficiency and lifetime. The organic light-emitting element includes a pair of electrodes and an organic compound layer placed between the pair of electrodes, in which the organic compound layer includes an iridium complex having a benzo[f]isoquinoline of a specific structure as a ligand and a heterocycle-containing compound of a specific structure..

10/15/15
20150290232 

Drug composition for treating tumors and application thereof


The present invention belongs to the field of medicine and pharmaceutical chemistry, specifically relates to novel antitumor pharmaceutical combination, and particularly relates to pharmaceutical combination of bisbenzylisoquinoline alkaloids (e.g. Berbamine and tetrandrine) and anthracene compounds (e.g.

10/15/15
20150290192 

Inhibitors of bruton's tyrosine kinase


This application discloses the btk inhibitor compounds 6-tert-butyl-8-fluoro-2-{3-hydroxymethyl-4-[1-methyl-5-(1′-methyl-1′,2′,3′,4′,5′,6′-hexahydro-[3,4′]bipyridinyl-6-ylamino)-6-oxo-1,6-dihydro-pyridazin-3-yl]-pyridin-2-yl}-2h-phthalazin-1-one, 2-(2-{3-[5-(5-azetidin-1-ylmethyl-1-methyl-1h-pyrazol-3-ylamino)-1-methyl-6-oxo-1,6-dihydro-pyridazin-3-yl]-2-hydroxy methyl-phenyl}-8-fluoro-1-oxo-1,2-dihydro-isoquinolin-6-yl)-2-methyl-propionitrile, and 6-tert-butyl-2-[2-hydroxymethyl-3-(5-{5-[(2-methoxy-ethylamino)-methyl]-pyridin-2-ylamino}-6-oxo-1,6-dihydro-pyridin-3-yl)-phenyl]-3,4-dihydro-2h-isoquinolin-1-one, formulations thereof, and methods of treatment of asthma, as described herein.. .

10/08/15
20150284332 

The synthesis of tetrahydroisoquinolines from 2-methyl-1-phenyl substituted indenes


A procedure for the synthesis of tetrahydroisoquinolines from 2-methyl-1-phenyl substituted indene is described. The process involves the use of osmium tetroxide to cleave the indene double bond forming the keto aldehyde product, which is then combined with a substituted amine forming the substituted isoquinoline.

10/01/15
20150274713 

Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin


With r1, r2, r3, r4, r5, r6, r7, r8, and r14 defined herein.. .

10/01/15
20150274671 

Guanidine and amine substituted tetrahydroisoquinoline compounds as factor xia inhibitors


The present invention provides compounds of formula (i): (formula (i)) or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..
Bristol-myers Squibb Company


09/24/15
20150267233 

Compositions and methods for producing benzylisoquinoline alkaloids


The present invention relates to host cells that produce compounds that are characterized as benzylisoquinolines, as well as select precursors and intermediates thereof. The host cells comprise one, two or more heterologous coding sequences wherein each of the heterologous coding sequences encodes an enzyme involved in the metabolic pathway of a benzylisoquinoline, or its precursors or intermediates from a starting compound.
California Institute Of Technology


09/24/15
20150266855 

Crystalline forms of a factor xia inhibitor


The instant invention provides crystalline forms of (s,e)-4-(2-(3-(3-chloro-2-fluoro-6-(1h-tetrazol-1-yl)phenyl)acryloyl)-5-(4-methyl-2-oxopiperazin-1-yl)-1,2,3,4-tetrahydroisoquinoline-1-carboxamido)benzoic acid and its solvates thereof; processes for the production of such crystalline forms; pharmaceutical compositions comprising such crystalline forms; and methods of treating thromboembolic disorders with such crystalline forms or such pharmaceutical compositions.. .
Bristol-myers Squibb Company


09/17/15
20150259358 

Guanidine substituted tetrahydroisoquinoline compounds as factor xia inhibitors


The present invention provides compounds of formula (i): or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..
Bristol-myers Squibb Company


09/10/15
20150252039 

Process for the preparation of pyrido[2,1-a] isoquinoline derivatives by catalytic asymmetric hydrogenation of an enamine


Wherein r2, r3, r4 and prot are as defined in the specification.. .

08/27/15
20150238488 

Drug composition for treating tumors and application thereof


The present invention belongs to the field of medicine and pharmaceutical chemistry, specifically relates to novel antitumor pharmaceutical combinations, and particularly relates to pharmaceutical combinations of bisbenzylisoquinoline alkaloids (e.g. Berbamine and tetrandrine) and imatinib mesylates and their use in treating tumors..
Hangzhou Bensheng Pharmaceutical Co., Ltd.


08/13/15
20150225348 

Process for preparing (1s)-1-phenyl-3,4-dihydro-2(1h)-isoquinoline-carboxylate


In formula i and ii, r is an alkyl or a substituted alkyl; lg is a leaving group.. .

08/06/15
20150218207 

N-substituted indenoisoquinolines and syntheses thereof


N-substituted indenoisoquinoline compounds, and pharmaceutical formulations of n-substituted indenoisoquinoline compounds are described. Also described are processes for preparing n-substituted indenoisoquinoline compounds.
The Government Of The United States Of America As Represented By The Secretary Of The Department Of


08/06/15
20150216181 

Pesticide having an insecticide, acaricide and nematicide action based on isoquinoline alkaloids and flavonoids


The present invention relates to a pesticide having an insecticide, acaricide and nematicide action obtained from plant extracts that have important synergic interactions in their pesticide activity, the characteristics of which are efficient control of insects, mites and nematodes; low toxicity for mammals and low persistence in the environment. This pesticide is a composition based on plant extracts which is characterized because it is constituted by: isoquinoline alkaloids and their derivatives (0.1-20%) and flavonoids and their glycosylated derivatives (0.001-10%).
Promotora Tecnica Industrial, S.a. De C.v.


07/30/15
20150210686 

(aza-)isoquinolinone derivatives


In which r1, x, y and n have the meanings indicated in claim 1, are inhibitors of tankyrase, and can be employed, inter alia, for the treatment of diseases such as cancer, cardiovascular diseases, central nervous system injury and different forms of inflammation.. .

07/30/15
20150209351 

Alpha adrenergic receptor modulators


Compounds are described herein useful for treating diseases and conditions by modulation of one or more alpha adrenergic receptor. The compounds can include a naphthalene, a quinoline, a benzoimidazole or an isoquinoline as a core structure.
Allergan, Inc.


07/09/15
20150191494 

Tetrahydroisoquinolines and intermediates therefor


Disclosed are processes for preparing tetrahydroisoquinolines, intermediates useful in the preparation of tetrahydroisoquinolines, processes for preparing such intermediates, and a crystalline form of 6-[(4s)-2-methyl-4-(naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine. Also disclosed are pharmaceutical compositions comprising tetrahydroisoquinolines, methods of using tetrahydroisoquinolines in the treatment of depression and other conditions and methods for obtaining the crystalline form..
Albany Molecular Research, Inc.


07/09/15
20150191453 

Asymmetrical reversible neuromuscular blocking agents of ultra-short, short, or intermediate duration


We describe ultra-short, short, and intermediate duration neuromuscular blocking compounds, reversible by cysteine or similar compounds, that are bisquaternary diesters of chlorofumaric, fumaric, or maleic acids where the quaternary groups are very different, creating a highly asymmetrical molecule where one quaternary includes an isoquinolinium ring system and the other includes a morpholinium, piperidinium, piperazinium, or pyrrolidinium system, pharmaceutical compositions, methods to use such compounds and compositions, and kits.. .
Cornell University


07/09/15
20150191450 

Isoquinoline-5-carboxamide derivative having inhibitory activity for protein kinase


A compound selected from the group consisting of an isoquinoline-5-carboxamide derivative of formula (i), a pharmaceutically acceptable salt, an isomer, a hydrate and a solvate thereof is effective for the prevention or treatment of diseases associated with abnormal cell growth, which are caused by abnormal activation of a protein kinases.. .
Hanmi Pharm. Co., Ltd.


06/25/15
20150175550 

Process for making isoquinoline compounds


The present invention relates to methods for making isoquinoline compounds and the intermediate compounds achieved thereby. Such compounds can be used to prepare compounds and compositions capable of decreasing hif hydroxylase enzyme activity, thereby increasing the stability and/or activity of hypoxia inducible factor (hif)..
Fibrogen, Inc.


06/18/15
20150166474 

Ionically bonded salt having reactive group and thermoplastic resin composition containing same


In chemical formulas (1) and (2) above, r1 and r2 each independently represent a substituted or unsubstituted linear, branched, or cyclic alkyl group having from 1 to 30 carbon atoms, a substituted or unsubstituted aryl group having from 6 to 30 carbon atoms, or a substituted or unsubstituted arylalkyl group having from 7 to 31 carbon atoms, a is a linear or branched alkylene group having from 2 to 4 carbon atoms, n represents an integer of 0 to 50, and q1 and q2 each independently represent at least one kind selected from the group consisting of an ammonium ion having an ethylenically unsaturated bond, an imidazolium ion having an ethylenically unsaturated bond, a pyridinium ion having an ethylenically unsaturated bond, a pyrrolidinium ion having an ethylenically unsaturated bond, a pyrrolinium ion having an ethylenically unsaturated bond, a piperidinium ion having an ethylenically unsaturated bond, a pyrazinium ion having an ethylenically unsaturated bond, a pyrimidinium ion having an ethylenically unsaturated bond, a triazolium ion having an ethylenically unsaturated bond, a triazinium ion having an ethylenically unsaturated bond, a quinolinium ion having an ethylenically unsaturated bond, an isoquinolinium ion having an ethylenically unsaturated bond, an indolinium ion having an ethylenically unsaturated bond, a quinoxalinium ion having an ethylenically unsaturated bond, a piperazinium ion having an ethylenically unsaturated bond, an oxazolinium ion having an ethylenically unsaturated bond, a thiazolinium ion having an ethylenically unsaturated bond, and a morpholinium ion having an ethylenically unsaturated bond.. .

06/11/15
20150158895 

Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde 10a)


Or a pharmaceutically acceptable salt thereof, wherein r′, r1 through r7 and ar are as defined herein. These compounds are useful as inhibitors of phosphodiesterase 10 (pde10a) which are useful in treating central nervous system diseases such as psychosis and also in treating, for example, obesity, type ii diabetes, metabolic syndrome, glucose intolerance, pain and ophthalmic diseases..

06/11/15
20150157624 

Substituted tetrahydroisoquinoline compounds as factor xia inhibitors


Or stereoisomers, pharmaceutically acceptable salts thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of factor xia and/or plasma kallikrein which may be used as medicaments..

05/28/15
20150148370 

Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase i inhibitors


The invention described herein pertains to substituted indenoisoquinoline compounds as described herein, wherein ra, rd, w, x and y are defined herein, pharmaceutical compositions and formulations comprising the indenoisoquinoline compounds, their synthesis, and methods for their use in the treatment and/or prevention of cancer.. .
Purdue Research Foundation


05/28/15
20150148292 

Bone morphogenetic protein pathway activation, compositions for ossification, and methods related thereto


The disclosure relates to compounds and compositions for bone formation, fracture treatment, bone grafting, bone fusion, cartilage maintenance and repair, and methods related thereto. In certain embodiments, the disclosure relates to compositions comprising one or more compound(s) disclosed herein, such as 2-(2-methoxybenzylidene)-1-indan-one; n-(4-arsonophenyl)glycine; 1,2-benzenedicarboxylic acid, 1-(1-methylheptyl)ester; (4′-hydroxybiphenyl-4-yl) (phenyl)methanone; 2,2-dimethylchroman-6-carboxylic acid, (4,7-dihydroxy-8-methyl-2-oxo-2h-chromen-3-yl)amide; ethyl 2-((4-chlorophenyl)thio)-1,3-benzothiazol-6-yl carbamate; ethyl (2-(azepan-1-yl)benzo[d]thiazol-6-yl) carbamate; porfiromycin; 1,3-benzodioxol-5-yl-[4-(3,4,5-trimethoxybenzoyl)-3-furyl]methanone; tricinolone acetophenonide; 2,4-bis(3,4-dimethoxyphenyl)-4h-pyrano[3,2-c]chromen-5-one; methyl 5-fluoro-4-methoxy-2,6-dioxohexahydro-5-pyrimidine carboxylate; 5-(naphthalen-1-yl)-1-phenyl-1h-tetrazole; 5-(2-phenylquinolin-4-yl)-1,3,4-oxadiazol-2-ol; n-[2,4,5-trimethyl-4-(trichloromethyl)cyclohexa-2,5-dien-1-ylidene]hydroxylamine; 4-benzoyl-3,4-dihydro-benzo[f]quinoline-3-carbonitrile; 2-nitro-3-phenylspiro[cyclopropane-1,9′-fluorene]; 3-[4-(furan-2-ylmethyl)-5-sulfanylidene-1,2,4-dithiazolidin-3-ylidene]-1,1-dimethyl-thiourea; (6-acetamido-7-methyl-5,8-dioxo-2,3-dihydro-1h-pyrrolo[1,2-a]benzimidazol-3-yl)2-methoxyacetate; 5-iodo-1h-indole-2,3-dione; 4,5-dihydro-1,2,9,10-tetramethoxy dibenzo[de,g]quinoline-6-carboxylic acid, ethyl ester; [2,6-bis(2,4-dimethylphenyl)-4-(2-methoxyacetyl)oxy-phenyl]2-methoxyacetate; 5,11-dimethyl-2-(2-piperidin-1-ylethyl)-6h-pyrido[4,3-b]carbazol-2-ium-9-ol; 2-[3-[[4-[(3-nitroacridin-9-yl)amino]phenyl]sulfamoyl]propyl]guanidine; 1-[[2-(dimethylamino)ethyl]amino]-7-hydroxy-4-methyl-9h-thioxanthen-9-one; 5-amino-1h-1,2,4-triazole-3-carboxylic acid, methyl ester; methyl n-cyano-n′-prop-2-en-1-ylcarbamimidothioate; 5,7-dinitro-8-quinolinol; 5-nitrosoquinolin-8-ol; cantharidin; 1,7-diaminoacridine; 3-methyl-3-(1-naphthyl)-2-benzofuran-1(3h)-one; dichlorolapachol; lycobetaine; 6-(1-aziridinyl)-2,3-dihydro-3-(propionyl)-7-methyl-1h-pyrrolo[1,8]-dione; 4-nitroestrone 3-methyl ether; 5,11-dimethyl-6h-pyrido[4,3-b]carbazole-1-carboxamide hydrochloride; 5-methoxysterigmatocysin; (6-acetamido-7-methyl-5,8-dioxo-2,3-dihydro-1h-pyrrolo[1,2-a]benzimidazol-3-yl)2-methoxyacetate; horminon; 7′,8′-dimethyl-2′-oxo-4′,4a′,6a′,7′-tetrahydro-2′h-spiro[oxirane-2,1′-pentaleno[1,6a-c]pyran]-5′-carboxylate; nybomycin acetate; 5h-[1,6]indeno[1,2-c]isoquinoline-5,12-dione; 2,3-dimethoxy-6-methyl-nitidine; iproplatin; 3-[(deoxyhexosyl)oxy]-2-(3,4-di-hydroxyphenyl)-6,8-dihdroxy-4h-1-benzopyran-4-one; 2-o-benzyl 8-o-methyl 3-(4-methylphenyl)sulfonyl-4,5-dioxo-6h-pyrrolo[3,2-e]indole-2,8-dicarboxylate; 6-bromo-5,8-dihydroxy-7-[4-[2-(2-hydroxyethoxy)ethyl]piperazin-1-yl]naphthalene-1,4-dione; 5-methylbenzo[c]phenanthridin-5-ium-2,3,8,9-tetrol; (6-acetyl-4-oxo-1,3-diphenyl-2-sulfanylidenethieno[2,3-d]pyrimidin-5-yl)-2,4-dichlorobenzoate; n—[c-[4-[bis(2-cyanoethyl)amino]-2-methylphenyl]-n-(4-methylanilino)carbonimidoyl]imino-4-methylbenzamide; gelcohol; curcumin; tirandamycin; noscapine; aristolochic acid; himbacine; fumagillin; fumitremorgin c; physalin b; derivatives, or salt thereof, for use in bone growth processes.
Emory University


05/28/15
20150144281 

Method of cleaning residue from a surface using a high efficiency disposable cellulosic wiper


An absorbent paper sheet for tissue or towel includes an amount by weight of pulp-derived papermaking fibers, and an amount by weight of fibrillated regenerated cellulosic microfibers prepared from a cellulosic dope of dissolved cellulose comprising a solvent selected from tertiary amine n-oxides, cellulose dissolving imidazolium salts, cellulose dissolving pyridinium salts, cellulose dissolving pyridazinium salts, cellulose dissolving pyrimidinium salts, cellulose dissolving pyrazinium salts, cellulose dissolving pyrazolium salts, cellulose dissolving oxazolium salts, cellulose dissolving 1,2,3-triazolium salts, cellulose dissolving 1,2,4-triazolium salts, cellulose dissolving thiazolium salts, cellulose dissolving piperidinium salts, cellulose dissolving pyrrolidinium salts, cellulose dissolving quinolinium salts, and cellulose dissolving isoquinolinium salts.. .
Georgia-pacific Consumer Products Lp


05/21/15
20150141431 

Pyrazinoisoquinoline compounds


Where the designation (r) indicates that the designated carbon has the (r) stereochemistry; and wherein z1 is hydrogen or fluorine; z2 is hydrogen, deuterium, or fluorine; z3 is deuterium; z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both z1 and z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel..

05/14/15
20150133666 

Tritoqualine for use in the treatment of cystic fibrosis


The present invention relates to the use of a histamine h4 agonist molecule, the enantiomers of the (amino-7 triethoxy-4,5,6 oxo-1 dihydro-1,3 isobenzofurannyl-3)-1methoxy-8 methyl-2 methylenedioxy-6,7 tetrahydro-,2,3,4 isoquinoline or tritoqualine for the treatment of respiratory impairment caused by cystic fibrosis and the reduction and prevention of bronchial superinfections.. .

05/14/15
20150133445 

Synthesis and use of dual tyrosyl-dna phosphodiesterase i (tdp1) - topoisomerase i (top1) inhibitors


The invention described herein pertains to the synthesis and use of certain n-substituted indenoisoquinoline compounds which inhibit the activity tyrosyl-dna phosphodiesterase i (tdp1) or topoisomerase i (top1) or both, or otherwise demonstrate anticancer activity. Also disclosed are novel n-substituted indenoisoquinoline compounds and pharmaceutical compositions comprising the novel n-substituted indenoisoquinoline compounds..

05/14/15
20150133443 

Thiazolyl- and oxazolyl-isoquinolinones and methods for using them


The present invention relates to substituted thiazolyl- and oxazolyl-isoquinolinones that act, for example, as modulators of poly(adp-ribose) polymerase (parp). The present invention also relates to processes for the preparation of substituted thiazolyl- and oxazolyl-isoquinolinones and to their use in treating various diseases and disorders..

05/07/15
20150126743 

Process for the preparation of pyrido [2,1-a] isoquinoline derivatives comprising optical resolution of an enamine


Wherein rco2− is the conjugate base of the resolving agent.. .

05/07/15
20150126517 

Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof


Novel aryl, heteroaryl, and non-aromatic heterocyle substituted tetrahydroisoquinolines are described in the present invention. These compounds are used in the treatment of various neurological and physiological disorders.
Albany Molecular Research, Inc.


04/30/15
20150119419 

6-aminoisoquinoline compounds


6-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided.
Aerie Pharmaceuticals, Inc.


04/30/15
20150119317 

Oral solid dosage formulation of 1,1-dimethylethyl [(1s)-1-carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate


The present invention is directed to an oral solid dosage formulation of asunaprevir, 1,1-dimethylethyl[(1s)-1-{[(2s,4r)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1r,2s)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate, and to methods of using the formulation in the treatment and/or inhibition of the hepatitis c virus and infections caused thereby.. .
Bristol-myers Squibb Company


04/23/15
20150112072 

Process of preparing solifenacin or salt thereof, and novel intermediate used in the process


Disclosed herein is a method of preparing solifenacin or a salt thereof, including the steps of: (a) reacting (r)-quinuclidinol with bis(pentafluorophenyl)carbonate in an organic solvent to prepare a solifenacin intermediate, (3r)-1-azabicyclo[2,2,2]oct-3-yl pentafluorophenylcarbonate, and (b) reacting the solifenacin intermediate with (1s)-1-phenyl-1,2,3,4-tetrahydroisoquinoline in an organic solvent to prepare solifenacin. The method is advantageous in that high-purity solifenacin or a salt thereof can be simply and efficiently prepared with high yield using a novel intermediate..
Kyung Dong Pharm. Co., Ltd.


04/16/15
20150105422 

Salts and solvates of a tetrahydroisoquinoline derivative


(s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid in substantially pure form is described together with its sodium salt and solvates. Methods for preparing the compound, its sodium salt and its solvates and pharmaceutical compositions comprising them are also described..
Spinifex Pharmaceuticals Pty Ltd


04/09/15
20150099732 

3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use


The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3-aryl-5-substituted-2h-isoquinolin-1-one compounds that, inter alia, inhibit parp (e.g., parp1, tnks1, tnks2, etc.) and/or wnt signalling.
Institute Of Cancer Research: Royal Cancer Hospital (the)


04/02/15
20150090639 

Halogen-free ionic liquids in naphtha desulfurization and their recovery


Ionic liquids of the general formula c+a− where c+ represents an organic cation, specifically, but not limited to the imidazolium, pyridinium, isoquinolinium, ammonium types, which have aliphatic and aromatic substituents, while a− represents a carboxylate, aromatic and aliphatic anion. The ionic liquids are synthesized under conventional heating or microwave irradiation this invention is also related to the application of ionic liquids to remove sulfur compounds of naphthas through a liquid-liquid extraction and the recovery and reuse of ionic liquids by the application of heat, reduced pressure and washing with solvents..
Instituto Mexicano Del Petroleo


03/26/15
20150087824 

Novel production isoquinoline derivatives and salts thereof


The present invention provides a method capable of industrially producing a target product, i.e., a compound represented by the aforementioned formula (i) or a salt thereof, which is useful for preventing and treating cerebrovascular disorders such as cerebral infarction, cerebral hemorrhage, subarachnoid hemorrhage, and cerebral edema, particularly for preventing and treating glaucoma, at high yield even on a large scale without imposing a negative impact on the environment. The present invention provides a method for producing a compound represented by formula (i) or a salt thereof, wherein the method comprises a step of reacting a compound represented by formula (iii) or a salt thereof with a compound represented by formula (ii) in the presence of at least one solvent selected from the group consisting of a nitrile solvent, an amide solvent, a sulfoxide solvent, and a urea solvent, and a base..
Kowa Co., Ltd.


03/12/15
20150073151 

Supercritical fluid extraction of bis-benzyl isoquinolines


An improved process for obtaining at least one bis-benzyl isoquinoline alkaloid from botanical material involves contacting the botanical material with a supercritical fluid having as a major component one or more aliphatic hydrocarbon compounds, such as alkanes, alkenes, cyclic aliphatic hydrocarbons, or a combination of these compounds.. .
Cba Pharma, Inc.


02/05/15
20150038529 

Crystalline forms of a prolyl hydroxylase inhibitor


The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.. .
Fibrogen, Inc.


02/05/15
20150038528 

4 -hydroxy- isoquinoline compounds as hif hydroxylase inhibitors


The present invention relates to novel compounds of formula (i), and compositions capable of inhibiting phd1 enzyme activity selectively over other isoforms, for example, phd2 and/or phd3 enzymes. The invention also relates to compounds of formula (i) for use in disorders such as muscle degeneration, colitis, ibd, and certain ischemias..
Fibrogen, Inc.


01/29/15
20150031893 

An h3 receptor antagonist for use in the treatment of alzheimer's disease


This disclosure relates to methods of using 2-(cyclohexylmethyl)-n-{2-[(2s)-1-methylpyrrolidin-2-yl]ethyl}-1,2,3,4-tetrahydroisoquinoline-7-sulfonamide in a disease modifying therapy of alzheimer's disease, other tauopathies and related neurodegenerative diseases.. .
Sanofi


01/29/15
20150031888 

Process for the preparation of pyrido[2,1-a] isoquinoline derivatives by catalytic asymmetric hydrogenation of an enamine


Wherein r2, r3, r4 and prot are as defined in the specification.. .

01/29/15
20150031696 

Cyanoisoquinoline compounds and methods of use thereof


The present invention relates to cyanoisoquinoline compounds suitable for use in treating hypoxia inducible factor-mediated and/or erythropoietin-associated conditions. The cyanoisoquinoline compounds of the invention have the following structure:.
Fibrogen, Inc.


01/22/15
20150021197 

Novel metal complex catalysts and uses thereof


The invention relates to novel metal complexes useful as catalysts in redox reactions (such as, hydrogen (h2) production). In particular, the invention provides novel transition metal (e.g., cobalt (co) or nickel (ni)) complexes, in which the transition metal is coupled with n,n-bis(2-pyridinylmethyl)-2,2′-bipyridine-6-methanamine (dpa-bpy), 6′-((bis(pyridin-2-ylmethyl)amino)methyl)-n,n-dimethyl-2,2′-bipyridin-6-amine (dpa-abpy), n,n-bis((isoquinolin-1-yl)methyl)(6-(pyridin-2-yl)pyridin-2-yl)methanamine (diq-bpy), or a derivative thereof.
University Of Memphis Research Foundation


12/25/14
20140378711 

Method for synthesizing 2,7-dimethyl-2,4,6-octatriene-1,8-dialdehyde


Provided in the present invention is a method for synthesizing 2,7-dimethyl-2,4,6-octatriene-1,8-dialdehyde. The synthesis method comprises the following steps: (1) adding acetaldehyde diethyl acetal and ethyl-(1-propenyl)-ether under the effect of a catalyst to produce 1,1,3-triethoxy-2-methyl-butane; (2) pyrolysis synthesizing 1,1,3-triethoxy-2-methyl-butane under the catalytic effects of isoquinoline and p-toluenesulfonic acid to produce 1-methoxy-2-methyl-1,3-butadiene; (3) dissolving 1-methoxy-2-methyl-1,3-butadiene in anhydrous ethanol solvent for synthesis with a phase transfer catalyst, cetyl-trimethyl ammonium bromide, and a chlorinating agent, trichloroisocyanuric acid, to generate 4,4-diethoxy-3-methyl-1-chloro-butene; (4) combining 4,4-diethoxy-3-methyl-1-chloro-butene with a triphenylphosphine salt to produce a phosphonium salt; and (5) condensing the phosphonium salt under the effects of hydrogen peroxide in conjunction with sodium carbonate solution to generate 1,1,8,8-tetramethyl-2,7-dimethyl-2,4,6-octatriene; then hydrolyzing under acidic conditions to synthesize 2,7-dimethyl-2,4,6-octatriene-1,8-dialdehyde.
Zhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory


12/25/14
20140378441 

Therapeutic agent for ocular fundus disease


Disclosed herein is a prophylactic or therapeutic agent for ocular fundus disease, especially diabetic retinopathy or age-related macular degeneration. The prophylactic or therapeutic agent for ocular fundus disease comprising: (s)-(−)-1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine, a salt thereof, or a solvate thereof, as an active ingredient..
Kowa Company, Ltd.


12/18/14
20140371450 

Processes for preparing isoquinolinones and solid forms of isoquinolinones


Polymorphs of chemical compounds that modulate kinase activity, including pi3 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including p13 kinase activity, are described herein. Also provided herein are processes for preparing compounds, polymorphs thereof, and pharmaceutical compositions thereof..
Infinity Pharmaceuticals, Inc.


12/11/14
20140364441 

Crystalline forms of (s)-7-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof


Novel [1,2,4]triazolo[1,5-a]pyridinyl-6-yl-substituted tetrahydroisoquinolines are described in the present invention. These compounds and crystalline forms sa1 and n-2 are used in the treatment of various neurological and physiological disorders.

12/04/14
20140357664 

3,4-dihydroisoquinolin-2(1h)-yl compounds


The invention provides certain 3,4-dihydroisoquinolin-2(1h)-yl compounds, particularly compounds of formula i, and pharmaceutical compositions thereof. The invention further provides methods of using a compound of formula i to treat cognitive impairment associated with parkinson's disease or schizophrenia..

12/04/14
20140357652 

Rho kinase inhibitors


Disclosed are novel substituted 2h-isoquinolin-1-one and 3h-quinazolin-4-one derivatives useful as inhibitors of rho kinase and for treating a variety of diseases and disorders that are mediated or sustained through the activity of rho kinase, including cardiovascular diseases, pharmaceutical compositions comprising such compounds, methods for using such compounds and processes for making such compounds.. .



Isoquinolin topics: Isoquinolin, Quinoline Derivatives, Carbon Atoms, Praziquantel, Crystallin, Pharmaceutically Acceptable Salt, Cycloalkyl, Alkyl Group, Sulfonamide, Solifenacin, Cancer Cells, Cancer Cell, Viral Infection, Human Immunodeficiency Virus, Immunodeficiency

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Isoquinolin for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Isoquinolin with additional patents listed. Browse our RSS directory or Search for other possible listings.


0.6298

4746

1 - 1 - 101